收费全文 | 976篇 |
免费 | 41篇 |
国内免费 | 2篇 |
儿科学 | 21篇 |
妇产科学 | 21篇 |
基础医学 | 66篇 |
口腔科学 | 25篇 |
临床医学 | 64篇 |
内科学 | 253篇 |
皮肤病学 | 13篇 |
神经病学 | 108篇 |
特种医学 | 21篇 |
外科学 | 198篇 |
综合类 | 2篇 |
预防医学 | 43篇 |
眼科学 | 16篇 |
药学 | 48篇 |
中国医学 | 13篇 |
肿瘤学 | 107篇 |
2023年 | 7篇 |
2022年 | 12篇 |
2021年 | 18篇 |
2020年 | 9篇 |
2019年 | 15篇 |
2018年 | 24篇 |
2017年 | 18篇 |
2016年 | 16篇 |
2015年 | 23篇 |
2014年 | 32篇 |
2013年 | 36篇 |
2012年 | 52篇 |
2011年 | 47篇 |
2010年 | 45篇 |
2009年 | 32篇 |
2008年 | 53篇 |
2007年 | 69篇 |
2006年 | 72篇 |
2005年 | 68篇 |
2004年 | 46篇 |
2003年 | 48篇 |
2002年 | 37篇 |
2001年 | 23篇 |
2000年 | 20篇 |
1999年 | 24篇 |
1998年 | 12篇 |
1997年 | 6篇 |
1996年 | 8篇 |
1995年 | 8篇 |
1994年 | 3篇 |
1992年 | 11篇 |
1991年 | 15篇 |
1990年 | 5篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 9篇 |
1986年 | 12篇 |
1985年 | 11篇 |
1984年 | 9篇 |
1983年 | 8篇 |
1981年 | 2篇 |
1980年 | 5篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1971年 | 4篇 |
1969年 | 3篇 |
1967年 | 2篇 |
The exercise pressor reflex is a feedback mechanism engaged upon stimulation of mechano- and metabosensitive skeletal muscle afferents. Activation of these afferents elicits a reflex increase in heart rate, blood pressure, and ventilation in an intensity-dependent manner. Consequently, the exercise pressor reflex has been postulated to be one of the principal mediators of the cardiorespiratory responses to exercise. In this updated review, we will discuss classical and recent advancements in our understating of the exercise pressor reflex function in both human and animal models. Particular attention will be paid to the afferent mechanisms and pathways involved during its activation, its effects on different target organs, its potential role in the abnormal cardiovascular response to exercise in diseased states, and the impact of age and biological sex on these responses. Finally, we will highlight some unanswered questions in the literature that may inspire future investigations in the field.
相似文献Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) leads to prolonged survival for selected patients with colorectal (CRC) peritoneal metastases (PM). This study aimed to analyze the prognostic role of micro-satellite (MS) status and RAS/RAF mutations for patients treated with CRS.
MethodsData were collected from 13 Italian centers with PM expertise within a collaborative group of the Italian Society of Surgical Oncology. Clinical and pathologic variables and KRAS/NRAS/BRAF mutational and MS status were correlated with overall survival (OS) and disease-free survival (DFS).
ResultsThe study enrolled 437 patients treated with CRS-HIPEC. The median OS was 42.3 months [95% confidence interval (CI), 33.4–51.2 months], and the median DFS was 13.6 months (95% CI, 12.3–14.9 months). The local (peritoneal) DFS was 20.5 months (95% CI, 16.4–24.6 months). In addition to the known clinical factors, KRAS mutations (p = 0.005), BRAF mutations (p = 0.01), and MS status (p = 0.04) were related to survival. The KRAS- and BRAF-mutated patients had a shorter survival than the wild-type (WT) patients (5-year OS, 29.4% and 26.8% vs 51.5%, respectively). The patients with micro-satellite instability (MSI) had a longer survival than the patients with micro-satellite stability (MSS) (5-year OS, 58.3% vs 36.7%). The MSI/WT patients had the best prognosis. The MSS/WT and MSI/mutated patients had similar survivals, whereas the MSS/mutated patients showed the worst prognosis (5-year OS, 70.6%, 48.1%, 23.4%; p = 0.0001). In the multivariable analysis, OS was related to the Peritoneal Cancer Index [hazard ratio (HR), 1.05 per point], completeness of cytoreduction (CC) score (HR, 2.8), N status (HR, 1.6), signet-ring (HR, 2.4), MSI/WT (HR, 0.5), and MSS/WT-MSI/mutation (HR, 0.4). Similar results were obtained for DFS.
ConclusionFor patients affected by CRC-PM who are eligible for CRS, clinical and pathologic criteria need to be integrated with molecular features (KRAS/BRAF mutation). Micro-satellite status should be strongly considered because MSI confers a survival advantage over MSS, even for mutated patients.
相似文献OBJECTIVES
- ? To evaluate the management of acute urinary retention (AUR) associated with benign prostatic hyperplasia (BPH) in real‐life practice.
- ? To identify predictors of successful trial without catheter (TWOC).
MATERIALS AND METHODS
- ? In all, 6074 men catheterized for painful AUR were enrolled in a prospective, cross‐sectional survey conducted in public and private urology practices in France, Asia, Latin America, Algeria and the Middle East.
- ? Patient clinical characteristics, type of AUR and its management (type of catheterization, hospitalization, TWOC, use of α1‐blockers, immediate or elective surgery) and adverse events observed during the catheterization period were recorded.
- ? Predictors of TWOC success were also analysed by multivariate regression analysis with stepwise procedure.
RESULTS
- ? Of the 6074 men, 4289 (71%) had a spontaneous AUR and 1785 (29%) had a precipitated AUR, mainly as the result of loco‐regional/general anaesthesia (28.5%) and excessive alcohol intake (18.2%).
- ? Presence of BPH was revealed by AUR in 44% of men. Hospitalization for AUR varied between countries, ranging from 1.7% in Algeria to 100% in France. A urethral catheter was inserted in most cases (89.8%) usually followed by a TWOC (78.0%) after a median of 5 days. Overall TWOC success rate was 61%.
- ? Most men (86%) received an α1‐blocker (mainly alfuzosin) before catheter removal with consistently higher TWOC success rates, regardless of age and type of AUR. Multivariate regression analysis confirmed that α1‐blocker before TWOC doubled the chances of success (odds ratio 1.92, 95% CI 1.52–2.42, P < 0.001).
- ? Age ≥70 years, prostate size ≥50 g, severe lower urinary tract symptoms, drained volume at catheterization ≥1000 mL and spontaneous AUR favoured TWOC failure. Catheterization >3 days did not influence TWOC success but was associated with increased morbidity and prolonged hospitalization for adverse events.
- ? In the case of TWOC failure, 49% of men were recatheterized and had BPH surgery and 43.5% tried another TWOC with a success rate of 29.5%. Elective surgery was preferred to immediate surgery.
CONCLUSIONS
- ? TWOC has become a standard practice worldwide for men with BPH and AUR.
- ? In most cases, an α1‐blocker is prescribed before TWOC and significantly increases the chance of success.
- ? Prolonged catheterization is associated with an increased morbidity.
Over the past years laser technology has played a predominant role in prostate surgery, for the treatment of benign prostate hypertrophy (BPH). Various laser devices have been introduced in clinical practice, showing good results in terms of complications and urodynamic outcomes efficacy compared with TURP and Open Prostatectomy.
In this study we describe the efficacy and the safety profile of a novel laser technique, ThuLEP (Thulium Laser Enucleation of Prostate) that permits a complete anatomical endoscopic enucleation of prostatic adenoma independently to prostate size.
Methods148 patients with a mean age of 68.2 years were enrolled between September 2009 and March 2012 (36 months), and treated for BPH with ThuLEP. Every patient was evaluated at base line according to: Digital Rectal Examination (DRE), prostate volume, Post-Voided volume (PVR), International Prostate Symptoms Score (I-PSS), International Index of Erectile Function-5 (IIEF-5), Quality of Life (QoL), PSA values, urine analysis and urine culture, uroflowmetry. The same evaluation was conducted after a 12 month follow-up. ThuLEP was performed by 2 expert surgeons.
ResultsOur data showed a better post-operative outcome in terms of catheter removal, blood loss, TURP syndrome, clot retention and residual tissue compared to large series of TURP and OP. Only 1.3% of patients had bladder wall injury during morcellation. I-PSS, Qmax, Prostate Volume, QoL and PVR showed a highly significant improvement at 12 month follow-up in comparison to preoperative assessment.
ConclusionThuLEP represent an innovative option in patients with BPH. It is a size independent surgical endoscopic technique and it can be considered the real alternative, at this time, to TURP and even more to Open Prostatectomy for large prostate, with a complete removal of adenoma and with a low complication rate.
相似文献